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Arsenic is both a human carcinogen causing
cancer in multiple tissues [National Research
Council (NRC) 1999, 2001] and a chemo-
therapeutic agent used in the treatment of
acute promyelocytic leukemia (Cohen et al.
2001). Arsenic trioxide shows promise for
chemotherapy in treatment of solid tumors
and inhibits tumor growth in an orthotopic
prostate cancer model (Maeda et al. 2001).
However, the mechanism by which arsenic
selectively induces cell death in tumor cells is
not understood. 
Clinically achievable concentrations of
arsenite induce cell death in a variety of cancer
cell lines and virally immortalized cell lines that
lack normal cell cycle control. Arsenic trioxide
(As2O3) induces apoptosis in several prostate
and ovarian cancer cell lines (Du and Ho 2001;
Uslu et al. 2000). Arsenite induces mitotic
arrest and apoptosis in SV40-transformed
human ﬁbroblasts (States et al. 2002), sponta-
neously immortalized p53-deficient Li-
Fraumeni human fibroblasts (Taylor et al.
2006), and in HeLa S3 and KB cells (Huang
and Lee 1998). In contrast, these moderate
concentrations of arsenite slow the growth of
diploid human ﬁbroblasts but do not induce
cell death (States et al. 2002; Yih et al. 1997).
However, arsenite disrupts normal mitotic pro-
gression and induces aneuploidy in human
diploid ﬁbroblasts (Yih et al. 1997) and periph-
eral blood lymphocytes (Vega et al. 1995).
A common feature of the cell lines in
which arsenite induces apoptosis is a p53-deﬁ-
cient phenotype, either by mutation or viral
oncogene inactivation of p53. p53 regulates
cell cycle progression and apoptosis in response
to genetic damage. The molecular mechanisms
by which p53 arrests cell cycle progression in
G1 and G2 phases in response to DNA damage
are reasonably well understood (Jin and Levine
2001). p53 is activated in response to mitotic
disruption by arsenic (Yih and Lee 2000).
However, the signals for p53 activation and
the role that p53 plays in the cellular response
to mitotic disruption are not clear. 
In asynchronous TR9-7 cells (human
fibroblasts with tetracycline-regulated p53
expression), arsenite treatment induces a p53-
independent accumulation of cells with
G2/M phase DNA content (Taylor et al.
2006). However, accumulation of mitotic
cells occurs in p53-deﬁcient [p53(–)] but not
in p53-expressing [p53(+)] TR9-7 cells.
Furthermore, the mitotically arrested p53(–)
cells undergo apoptosis, whereas most p53(+)
cells exit G2/M phase and arrest in G1 phase.
Therefore, we hypothesized that p53 did not
prevent delayed G2 transit but did protect
against apoptosis subsequent to the arsenite-
induced mitotic arrest. 
To investigate the role of p53 in the arsen-
ite-induced disruption of G2/M phase pro-
gression, we examined the response of p53(+)
and p53(–) TR9-7 cells to arsenite treatment
after release from G2 phase synchrony. We
show that in synchronized TR9-7 cells arsen-
ite delayed entry into mitosis independently of
p53 expression but that the exit from mitosis
in arsenite-treated cells was p53 dependent.
Furthermore, we show that the apoptotic
process occurred while the cells attempted
cytokinesis. We hypothesized the difference in
exit kinetics and resistance to apoptosis
between p53(+) and p53(–) cells was due to
p53-mediated alterations of gene expression
profiles. Microarray analysis of G2 phase–
synchronized p53(+) and p53(–) cells treated
with arsenite for 3 hr revealed p53-dependent
induction of inhibitor of DNA binding-1
(ID1). Negative transcriptional regulation of
cyclin-dependent kinase inhibitors by ID1
may have implications for cell cycle progres-
sion in p53(+) cells surviving arsenite-induced
mitotic perturbation and may play a role in
arsenic-induced carcinogenesis.
Materials and Methods
Cell culture and synchronization. TR9-7 
cells were the gift of  M.A. Tainsky (Wayne
State University, Detroit, MI). Cells were cul-
tured at 37ºC at 5% CO2 in a humidified
incubator in alpha modification of minimal
essential media (GIBCO/BRL, Gaithersburg,
MD) supplemented with 10% fetal bovine
serum (HyClone, Logan, UT), 10 mM HEPES
(pH 7.0), 200 μg/mL geneticin (Invitrogen
Corp., Carlsbad, CA), 40 μg/mL hygro-
mycin B (Sigma Chemical Co., St. Louis,
MO), 100 U/mL penicillin, and 10 U/mL
streptomycin. 
Cells were synchronized in G2 phase of the
cell cycle according to adaptation of published
procedures (Kuhholzer and Prather 2001;
Tobey et al. 1990). Brieﬂy, we plated cells in
the presence of 15 ng/mL tetracycline (Fisher
Scientiﬁc, Pittsburgh, PA) to allow moderate
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BACKGROUND: Arsenic is both a human carcinogen and a chemotherapeutic agent, but the mecha-
nism of neither arsenic-induced carcinogenesis nor tumor selective cytotoxicity is clear. Using a
model cell line in which p53 expression is regulated exogenously in a tetracycline-off system
(TR9-7 cells), our laboratory has shown that arsenite disrupts mitosis and that p53-deﬁcient cells
[p53(–)], in contrast to p53-expressing cells [p53(+)], display greater sensitivity to arsenite-induced
mitotic arrest and apoptosis.
OBJECTIVE: Our goal was to examine the role p53 plays in protecting cells from arsenite-induced
mitotic arrest. 
METHODS: p53(+) and p53(–) cells were synchronized in G2 phase using Hoechst 33342 and released
from synchrony in the presence or absence of 5 µM sodium arsenite.
RESULTS: Mitotic index analysis demonstrated that arsenite treatment delayed exit from G2 in
p53(+) and p53(–) cells. Arsenite-treated p53(+) cells exited mitosis normally, whereas p53(–) cells
exited mitosis with delayed kinetics. Microarray analysis performed on mRNAs of cells exposed to
arsenite for 0 and 3 hr after release from G2 phase synchrony showed that arsenite induced
inhibitor of DNA binding-1 (ID1) differentially in p53(+)and p53(–) cells. Immunoblotting con-
ﬁrmed that ID1 induction was more extensive and sustained in p53(+) cells. 
CONCLUSIONS: p53 promotes mitotic exit and leads to more extensive ID1 induction by arsenite.
ID1 is a dominant negative inhibitor of transcription that represses cell cycle regulatory genes and
is elevated in many tumors. ID1 may play a role in the survival of arsenite-treated p53(+) cells and
contribute to arsenic carcinogenicity.
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containing 5 μg/mL aphidicolin (Sigma) and
incubated the cells for 24 hr. We then washed
the cells with phosphate-buffered saline (PBS)
and incubated them in media containing
0.1 μg/mL Hoechst 33342 (Sigma) for 12 hr.
After 6 hr of incubation with Hoechst 33342,
p53 expression was suppressed in half the cul-
tures by direct addition of tetracycline
(1 mg/mL) to the media to a ﬁnal concentra-
tion of 1,500 ng/mL. Cells were released from
G2 phase by washing with PBS and refeeding
with fresh drug-free media.
Arsenic compounds. We prepared fresh
working aqueous solutions of sodium arsenite
(NaAsO2) (Sigma) on the day of treatment
and ﬁlter sterilized prior to use.
Flow cytometry. For DNA content analy-
sis, cells were harvested by trypsinization and
ﬁxed in 1 mL ice-cold 70% ethanol. Following
ﬁxation overnight at 4ºC, we centrifuged the
samples at 1,500 × g and resuspended the
resulting cell pellets in PBS containing propid-
ium iodide and 100 U/mL RNase A (Sigma)
for 30 min at room temperature. We analyzed
propidium iodide–stained samples on a
FACSCalibur (Becton Dickinson and Co., San
Jose, CA) using doublet discrimination.
Propidium iodide fluorescence was collected
on channel two (FL2) (585/42 nm) using lin-
ear amplification. A minimum of 20,000
events/sample was analyzed. Data were col-
lected using CellQuest software (Becton
Dickinson) and analyzed for cell cycle distribu-
tion using Modfit software (Verity Software
House, Inc., Topsham, ME). 
Mitotic indices. Cells were harvested for
mitotic index analysis by trypsinization. Media,
wash, and cells were collected together and
centrifuged. We resuspended cell pellets  in
150 μL serum free media and added 2.5 mL of
0.4% KCl. We incubated the suspension for
10 min at 37ºC, then added methanol:acetic
acid fixative solution (3:1, vol/vol) to 2%
(vol/vol) and collected cells by centrifugation.
Cells were resuspended in 2.5 mL ﬁxative solu-
tion and ﬁxed at room temperature for 20 min.
Samples were centrifuged; cell pellets were
resuspended in 0.5 mL ﬁxative and chilled on
ice for 1 hr. Aliquots of the suspensions were
dropped onto glass slides, air dried, and stained
with Wright Giemsa solution (Fisher). We
examined slides under a microscope and
counted a minimum of 200 cells to determine
mitotic index.
Western blot analyses. Media from culture
dishes were removed and collected along with
one PBS wash. Floating cells were pelleted via
centrifugation, washed once with PBS, and
lysed with lysis buffer [10 mM Tris–HCl
(pH 7.4), 1 mM Na2–EDTA, 0.1% SDS,
180 μg/mL phenylmethylsulfonyl fluoride].
Adherent cells were lysed directly in the plates.
Lysates from floating and adherent fractions
were then combined. Protein concentration in
the lysates was determined by Bradford assay
(BioRad Laboratories, Inc., Hercules, CA).
Proteins were resolved by SDS–PAGE in 12%
polyacrylamide gels and transferred to sup-
ported nitrocellulose membranes by electro-
blotting. p53, β-actin, and ID1 were detected
by probing membranes with antibodies for
p53  (LabVision, Fremont, CA), β-actin
(Sigma), or ID1 (Santa Cruz Biotechnologies,
Santa Cruz, CA), respectively. Blots were
incubated with secondary anti-mouse or anti-
rabbit antibody conjugated to horse radish
peroxidase (Zymed Laboratories, San
Francisco, CA) and visualized with enhanced
chemiluminescence (Amersham Biosciences
Inc., Piscataway, NJ).  
Statistical analyses. Comparison of
mitotic indices of arsenite-treated p53(+) and
p53(–) cells was performed by Student t-test
using SlideWrite software (version 6.10;
Advanced Graphics Software, Encinitas, CA)
and confirmed by analysis of variance
(ANOVA).
Microarray analyses. We harvested cells
via trypsinization and prepared poly(A)+
mRNAs using Micro-FastTrack (Invitrogen
Corp.). SuperScript II (Invitrogen Corp.) was
used with an oligo(dT) primer linked to the
T7 RNA polymerase-binding site sequence to
synthesize cDNAs. cDNAs were extracted
with phenol:chloroforam:isoamyl alcohol
(25:24:1), precipitated with NH4OAc and
ethanol, and resuspended in RNase-free water.
We synthesized biotin-labeled cRNA with an
ENZO RNA transcript labeling kit (Enzo Life
Sciences, Farmingdale, NY), using 0.7 μg
cDNA per reaction. cRNAs were puriﬁed with
RNeasy purification columns (Qiagen,
Valencia, CA). cRNA, 15 μg per sample, was
heated at 80ºC for 33 min in fragmentation
buffer (Affymetrix, Inc., Santa Clara, CA).
Fragmented cRNAs were hybridized to
U95Av2 GeneChips (Affymetrix) for 16 hr 
at 45ºC. GeneChips were stained with
streptavidin phycoerythrin stain solution
(Affymetrix). Signal was amplified with goat
anti-streptavidin antibody and biotinylated
goat IgG (Affymetrix). We scanned stained
GeneChips on an Agilent GeneArray Scanner
(Agilent Technologies, Palo Alto, CA) and
performed four biological replicates. 
McNeely et al.
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Figure 1. Synchronization of TR9-7 cells expressing or not expressing p53 in G2 phase. Abbreviations:
FL2-A, propidium iodide ﬂuorescence on channel two; Tet, tetracycline. (A) Experimental design. (B) Cell
cycle distribution of synchronized cells. Samples were harvested after treatments indicated and analyzed
by ﬂow cytometry. Positions of cells with G1 and G2/M phase DNA content are indicated.
Tetracyline
Time (hr)
p53
ID1
β-Actin
036 1 2 1 6 2 4
0 μM NaAsO2
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3 6 12 16 24 0 3 6 12 16 24 3 6 12 16 24
1,500 ng/mL
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Figure 2. p53 and ID1 expression in cells after G2 phase synchronization. Cells were synchronized, treated
with 5 µM NaAsO2, and samples were taken at the indicated times. Levels of p53 and ID1 proteins were
assessed by Western blot analysis with β-actin as a loading control. 0 hr = release from Hoechst 33342. 
A representative example is shown. We performed ANOVA of the signal data
with Bioconductor/R software using MAS
(Microarray Suite software) background cor-
rection, quantiles normalization, MAS PM
(perfect match) correction, MAS summary,
and statistical signiﬁcance deﬁned as p < 0.05.
Data were ﬁltered on p53 status and arsenite
exposure. Analysis was conducted with and
without application of the Benjamini and
Hochberg false discovery rate correction. Venn
analysis was conducted on gene lists using
GeneSpring software (Agilent Technologies).
Results
To determine the role that p53 plays in pre-
venting arsenite-induced accumulation of
mitotic cells and in preventing arsenite-
induced apoptosis, TR9-7 cells were synchro-
nized in G2 using Hoechst 33342. Hoechst
33342 is a topoisomerase inhibitor that inter-
feres with chromatin condensation, resulting
in G2 phase arrest (Kuhholzer and Prather
2001). The effects of arsenite treatment on the
progression from G2 phase and through mito-
sis of synchronized p53(+)) and p53(–) cells
were evaluated after release from Hoechst
33342-induced G2 phase synchronization. 
TR9-7 cells are a spontaneously immor-
talized human fibroblast cell line, derived
from a Li-Fraumeni patient, and subsequently
stably transfected with a tetracycline-regulated
p53 expression vector (Yin et al. 1992). p53
expression in TR9-7 cells is inversely propor-
tional to the tetracycline concentration in the
media (tet-off). Absence of tetracycline
strongly induces p53 and causes TR9-7 cells
to arrest in G1 and G2 phases (Agarwal et al.
1995). Tetracycline at a concentration of
15 ng/mL induces p53 to a modest level that
allows the cells to grow at a rate comparable
to p53(–) TR9-7 cells (Taylor et al. 2006).
Synchronization of TR9-7 cells in G2 phase
using Hoechst 33342. Synchronization of
TR9-7 cells in G2 phase required plating cells
with moderate p53 expression. Cells with high
levels of p53 tended to arrest in G1 or G2
phase and not re-enter the cell cycle. In addi-
tion, induction of p53 by lowering the tetra-
cycline concentration proved difﬁcult to time
reproducibly. We obtained reproducible
changes in p53 expression by repressing p53 by
addition of tetracycline (data not shown). The
experimental design we developed is presented
in Figure 1. Cells were synchronized in G1
phase by addition of aphidicolin after allowing
freshly plated cells to attach and to acclimate
for 24 hr. Cells were released from G1 phase
synchrony after 24-hr aphidicolin exposure by
washing the cells and applying fresh media
containing Hoechst 33342, which induced G2
phase synchrony. After 6 hr of incubation in
Hoechst 33342 media, p53 transcription was
suppressed in half the cultures by addition of
tetracycline to 1,500 ng/mL. Cells were incu-
bated for an additional 6 hr. At this point,
media were changed again and half of each
tetracycline group received media containing 0
or 5 μM NaAsO2 with tetracycline appropriate
to maintain p53 expression levels. Samples
were taken at each change of media and at
several time points post-Hoechst 33342 incu-
bation. Samples were analyzed with flow
cytometry to determine cell cycle distribution
(Figure 1B), by Western blot to determine p53
and ID1 expression  (Figure 2), and for mitotic
spread analysis to determine mitotic index
(Figure 3A). We performed microarray analysis
to determine changes in gene expression
(Tables 1–3).
Cell cycle distribution of synchronized cells.
Using the procedure depicted in Figure 1A, we
were able to achieve reasonably good synchro-
nization. Unsynchronized TR9-7 cells show a
typical cell cycle distribution with a majority of
the cells in G1 phase and a distinct but small
G2/M phase peak (Figure 1B). After aphidi-
colin treatment, > 90% of cells were in the G1
phase (Figure 1B). After incubation with
Hoechst 33342, approximately 60% of the
cells were in G2 phase, as characterized using
ModFit software to analyze the ﬂow cytometry
data (Figure 1B). The approximately 40% of
cells remaining in G1 phase appeared irre-
versibly arrested in G1. 
p53 expression in cells after G2 synchro-
nization. p53 levels were assessed in cells during
synchronization and after release from G2
phase. Generally, p53 expression was main-
tained consistently in cultures with low tetra-
cycline and suppressed by tetracycline at
1,500 ng/mL throughout the experiment
(Figure 2). The achievement of a high level of
synchrony in the cultures required the moder-
ate expression of p53 that was suppressed by
addition of tetracycline at 1,500 ng/mL 6 hr
prior to release from G2 phase blockade. A
modest amount of residual p53 was detectable
in 1,500 ng/mL tetracylcline cultures [p53(–)] at
0 and 3 hr after release, although p53 expres-
sion was much lower than that observed in cul-
tures with only 15 ng/mL tetracycline [p53(+)]. 
Arsenite delays mitotic exit selectively in
p53(–) cells. We examined arsenite effects on
entry into and exit from mitosis in syn-
chronized cells. Mitotic indices and p53
p53 alters exit from mitotic arrest by arsenite
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Table 1. Arsenite-dependent gene induction detected by microarray analysis at 0 and 3 hr after release
from G2 phase synchrony with FDR applied.a
Fold-change
UniGene ID Probe set ID Gene title Gene symbol p53(+) p53(–)
517581 33802_at heme oxygenase (decycling) 1 HMOX1 27.2 26.1
504609 36618_g_at inhibitor of DNA binding 1 ID1 6.9 4.3
418241 39081_at metallothionein 2A MT2A 3.9 3.6
519469 34759_at solute carrier family 30 (zinc transporter), member 1 SLC30A1 3.2 3.1
504609 36619_r_at inhibitor of DNA binding 1 ID1 3.8 2.7
504609 36617_at inhibitor of DNA binding 1 ID1 3.7 2.5
534330 36130_f_at metallothionein 1E (functional) MT1E 1.9 1.9
513626 31622_f_at metallothionein 2A MT2A 1.9 1.8
284141 33835_at TSPY-like 4 TSPYL4 1.7 1.9
282326 32168_s_at Down syndrome critical region gene 1 DSCR1 1.6 1.8
37055 1732_at ﬁbroblast growth factor 5 FGF5 1.7 1.6
440939 31623_f_at metallothionein 2A MT2A 1.6 1.5
105269 33369_at sterol-C4-methyl oxidase-like SC4MOL 1.4 1.5
467020 1700_at BCL2 binding component 3 BBC3 0.7 0.6
503093 32588_s_at zinc ﬁnger protein 36, C3H type-like 2 ZFP36L2 0.4 0.3
aGene annotations from NetAffx (http://www.affymetrix.com/analysis/index.affx).
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Figure 3. Arsenite treatment delays mitotic entry,
and p53 deficiency delays mitotic exit in arsenite-
treated cells. Abbreviations: As(+), + 5 µg sodium
arsenite; As(–), 0 µg sodium arsenite. (A) Mitotic
indices of TR9-7 cells released from G2 phase syn-
chronization. Mean ± SD from four independent
experiments performed with triplicate cultures are
plotted. Not all time points assayed in every experi-
ment. (B) Arsenite-treated TR9-7 cells in late
anaphase/early telophase undergoing apoptosis.
Cells were released from G2 phase by feeding with
fresh media containing 5 µM NaAsO2 and monitored
by phase microscopy. Photographs in panels 1–8
were taken in order over a 30-min period. Bar, 5 µm.
*Significant difference between arsenite-exposed p53(+)
and p53(–) cells. expression were determined in triplicate
cultures exposed or not exposed to 5 μM
NaAsO2 and harvested 0, 1, 3, 6, 12, 16, 20
and 24 hr after release from G2 phase syn-
chrony induced by Hoechst 33342 exposure.
Mitotic indices were determined only in
experiments in which the p53 expression was
maintained as expected. The mitotic index of
cells not exposed to arsenite peaked 3 hr after
release from G2 phase (Figure 3A). There was
no difference between p53(+) and p53(–) cells.
The mitotic index dropped sharply after 3 hr
and was < 1% by 12 hr. The mitotic index
started to increase again 24 hr after release
from G2 phase, indicating that the cells had
started to cycle again. Arsenite treatment
delayed the peak in mitotic index to 6 hr after
release from G2 phase in both p53(+) and
p53(–) cells. The mitotic index of p53(+) cells
treated with arsenite decreased after 6 hr and
returned to baseline by 16 hr. The slope of
the decrease in mitotic index of arsenite-
treated p53(+)  cells is similar to that of the
decline in cells not exposed to arsenite. These
results suggest that entry into mitosis is
delayed in p53(+) cells but that mitotic exit is
normal. In contrast, the mitotic index of
p53(–) cells treated with arsenite dropped
slowly and was still significantly elevated
16 hr (p < 0.001, n = four experiments) after
release from G2 phase arrest. The mitotic
index dropped to nearly zero by 24 hr after
release from G2 phase. 
Arsenite induces alteration of expression
profiles. Microarray analysis was conducted
on mRNAs prepared from p53(+) and p53(–)
cells at 0 and 3 hr after release from G2 phase
synchrony with or without arsenite exposure.
ANOVA of four biological replicates using a
p < 0.05 was performed with Bioconductor/R
software using MAS background correction,
quantiles normalization, MAS PM correction,
and MAS summary. Analysis was conducted
with (Table 1) and without (Tables 2, 3)
application of the Benjamini and Hochberg
false discovery rate (FDR) correction. Table 1
is all inclusive, whereas Table 2 includes only
those genes showing ≥ 2-fold increase in
either p53(+) or p53(–) samples. Arsenite
induced several genes independently of p53
status. Heme oxygenase 1 (HMOX1) showed
a dramatic > 25-fold increase in expression.
Metallothioneines 2A and 1X and the zinc
transporter SLC30A1 were also induced.
Expression of the stress-responsive heat shock
protein HSP70B was elevated > 7-fold. ID1
was induced 3.7- to 6.9-fold in p53(+) cells
and 2.5- to 4.3-fold in p53(–) cells depending
on which of three probe sets was evaluated.
Although two-way ANOVA did not indicate
that the difference in fold-change between
p53(+) and p53(–) cells was statistically signiﬁ-
cant, Western blot analysis did show ID1
induction that was more extensive and sus-
tained in p53(+) cells (Figure 2). Two-way
ANOVA did not identify any genes or which
expression was dependent on p53; therefore,
Venn analysis was performed with GeneSpring
software (Agilent Technologies) on lists of
genes altered in p53(+) and p53(–) samples by
arsenite treatment. The false discovery rate
correction was not applied. This approach
identiﬁed several genes altered by arsenite in
only p53(+) or p53(–) (Table 3). For example,
MAP kinase phosphatase 1 (MKP-1) was
induced only in p53(+) cells and ubiquitin-
conjugating enzyme E2N was induced only in
p53(–) cells.  
Arsenite induces cytokinesis failure and
apoptosis. An example of a mitotic cell under-
going apoptosis in an arsenite-treated culture is
shown in Figure 3B. Mitosis, from the start of
prophase to the completion of cytokinesis, nor-
mally takes < 30 min in these cells. As can be
observed in Figure 3B, 30 min elapsed from the
time a cell was in late anaphase/early telophase
(panel 1) to when the cell collapsed (panel 8).
The metaphase plates holding the chromo-
somes did not change position while the mem-
brane developed multiple blebs (panels 1–4).
The chromosomes appeared to partially decon-
dense (panel 5). The cell body collapsed
between the plates but the membranes did not
fuse to complete cytokinesis (panels 6–8). 
Discussion
Arsenite (as either NaAsO2 or As2O3) is
known to activate the G2 phase checkpoint
(Chen et al. 2002) and to induce mitotic
arrest and apoptosis in a variety of cell lines
including HeLa (Huang and Lee 1998),
U937 (Halicka et al. 2002; McCabe et al.
2000), SV40-transformed human fibroblasts
(Halicka et al. 2002; McCabe et al. 2000;
States et al. 2002), and several prostate and
ovarian carcinoma cells (Uslu et al. 2000). A
common feature of the cells in which arsenite
induces both mitotic arrest and apoptosis is a
functional loss of p53. We have shown that
arsenite-induced mitotic arrest occurs in asyn-
chronous cells lacking p53 expression but not
in cells expressing p53 (Taylor et al. 2006). In
the present study, we have determined
whether p53 expression affects the progres-
sion of arsenite-treated cells from G2 phase
into M phase and/or the exit from mitosis. 
TR9-7 cells are a well-characterized model
to study p53-dependent processes, taking
advantage of tetracycline-regulated p53 expres-
sion (Adimoolam and Ford 2002; Agarwal
et al. 1995; Ford and Hanawalt 1997; Lloyd
and Hanawalt 2002; Robles et al. 2001; Taylor
McNeely et al.
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Table 3. p53-dependent gene induction by arsenite determined by Venn analysis (FDR not applied).a
Unigene ID Probe set ID  Gene title Gene symbol Fold-change
P53(+) cells
520028 31692_at heat shock 70kDA protein 1A HSPA1A 4.7
419 34585_at distal-less homeo box 2 DLX2 2.3
171695 1005_at dual speciﬁcity phosphatase 1 (MKP-1) DUSP1 2.1
P53(–) cells
142912 36799_at frizzled homolog 2 (Drosophila) FZD2 4.2
50308 40121_at huntingtin interacting protein 2 HIP2 2.5
93002 1651_at ubiquitin-conjugating enzyme E2C UBE2C 2.2
524630 36604_at ubiquitin-conjugating enzyme E2N UBE2N 2.2
aGene annotations from NetAffx (http://www.affymetrix.com/analysis/index.affx).
Table 2. Arsenite-dependent gene induction detected by microarray analysis at 0 and 3 hr after release
from G2 phase synchrony with FDR not applied.a
Fold-change
UniGene ID Probe set ID Gene title Gene symbol p53(+) p53(–)
517581 33802_at heme oxygenase (decycling) 1 HMOX1 27.2 26.1
3268 35965_at heat shock 70k protein 6 (HSP70B’) HSPA6 8.5 6.9
504609 36618_g_at inhibitor of DNA binding 1 ID1 6.9 4.3
520028 1104_s_at heat shock 70kDa protein 1A HSPA1A 5.8 4.9
418241 39081_at metallothionein 2A MT2A 3.9 3.6
609521 34759_at solute carrier family 30 (zinc transporter), member 1 SLC30A1 3.2 3.1
504609 36619_r_at inhibitor of DNA binding 1 ID1 3.8 2.7
504609 36617_at inhibitor of DNA binding 1 ID1 3.7 2.5
374950 39120_at metallothionein 1X MT1X 3.3 4.5
148340 41215_s_at inhibitor of DNA binding 2 ID2 3.1 2.8
799 38037_at diphtheria toxin receptor DTR 2.8 1.9
153863 1955_s_at SMAD, mothers against DPP  SMAD6 2.4 2.0
homolog 6
76884 37043_at inhibitor of DNA binding 3 ID3 2.4 2.5
491611  1137_at solute carrier family 20 member 2 SLC20A2 2.2 2.3
517617 36711_at v-maf  musculoaponeurotic MAFF 2.2 1.9
ﬁbrosarcoma oncogene
520819 35303_at insulin induced gene 1 INSIG1 2.1 1.8
196054 37483_at histone deacetylase 9 HDAC9 2.1 1.7
aGene annotations from NetAffx (http://www.affymetrix.com/analysis/index.affx).p53 alters exit from mitotic arrest by arsenite
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et al. 2001) We synchronized these human
ﬁbroblasts in G2 phase using a multi-step pro-
tocol developed by others (Kuhholzer and
Prather 2001; Tobey et al. 1990) and adapted
to our experiments. The fraction of the cells in
G2 phase was not as high as some investigators
have achieved with normal diploid ﬁbroblasts
(Tobey et al. 1990) but higher than that
achieved by another group (Kuhholzer and
Prather 2001). 
Our results indicate that arsenite exposure
delays progression from G2 phase to M phase
in both p53(–) and p53(+) cells. This result is
consistent with reported arsenite-induced G2
phase delay (McCollum et al. 2005; Park et al.
2001). However, the exit from mitosis was
delayed only in p53(–) cells. The mitotic index
in arsenite-treated p53(+) cells declined with
the same kinetics as in untreated cells. The
mitotic index declined more slowly in arsen-
ite-treated p53(–) cells, suggesting that these
cells exit mitosis more slowly. The arsenite-
treated cells entered apoptosis while futilely
attempting cytokinesis. These data indicate
that arsenite delays entry into mitosis and pro-
gression to anaphase in TR9-7 cells regardless
of p53 expression but that exit from mitosis is
p53 dependent in arsenitetreated cells. Thus,
both entry into and exit from mitosis is
delayed in p53(–) cells. Furthermore, the
p53(–) cells undergo apoptosis as a result of
failed or abnormal mitotic exit.
As p53 is a transcription factor, we
hypothesized that expression profile changes
could contribute to delayed mitotic exit kinet-
ics seen in p53(–) cells. To test this, we per-
formed microarray analysis of RNAs prepared
from G2 phase synchronized p53(+) and p53(–)
cells harvested at 0-hr and after 3-hr exposure
to 5 μM sodium arsenite. HMOX1 was highly
and rapidly induced, independently of p53.
HMOX1 induction is a well-documented
response to arsenite (Andrew et al. 2003; Liu
et al. 2001). HMOX1 induction is associated
with cellular response to oxidative damage, as
the degradation products of heme are known
to scavenge free radicals (Abraham 2003). 
The induction of metallothioneins 2A and
3 may also serve a protective role, as metalloth-
ionein has been shown to bind arsenicals (Jiang
et al. 2003) and metallothionein null mice are
hypersensitive to arsenite toxicity (Liu et al.
2000). MKP1, a phosphatase, was induced in
p53(+) cells and may serve a protective role as it
opposes the activation of SAPK/JNK (Li et al.
2003), a kinase involved in the induction of
apoptosis by arsenite (Davison et al. 2004),
MKP1 is a transcriptional target of p53 (Li
et al. 2003) and has been shown to be arsenite-
induced (Li et al. 2001). The expression of
ID1 was elevated by arsenite and Western blot
analysis showed the extent of induction was
greater and more sustained in p53(+) cells. ID1
is a dominant negative inhibitor of transcrip-
tion that forms inactive heterodimers with
basic helix–loop–helix transcription factors.
Genes identiﬁed as targets of repression by ID1
include those encoding the cyclin-dependent
kinase inhibitory proteins p15INK4B, p16INK4A,
and p21CIP1/WAF1 (Sikder et al. 2003). Our pre-
vious results indicate that the increased sensi-
tivity to mitotic arrest associated apoptosis of
p53-deficient cells is due to the lack of
p21CIP1/WAF1, a transcriptional target of p53
(Taylor et al. 2006). p21CIP1/WAF1 may prevent
mitotic arrest associated apoptosis in p53(+)
cells by allowing for mitotic exit of cells
arrested in mitosis. Mitotic exit requires the
destruction of cyclin B or inhibition of the
cyclin B/CDC2 complex. The promotion of
mitotic exit by p21CIP1/WAF1 would involve its
direct inhibition of cyclin B/CDC2 (Taylor
and Stark 2001). However, once p53(+) cells
exit mitosis, cell cycle progression would
require the inhibition of p21CIP1/WAF1. The
induction of ID1 by arsenite may serve to
repress p21CIP1/WAF1 and allow for continued
cell cycle progression (Figure 4).
Ectopic overexpression of ID1 immortal-
izes primary keratinocytes (Alani et al. 1999)
and a portion of the ID1 localizes to centro-
somes, causing abnormal centrosome number
(Hasskarl et al. 2004). Centrosomes serve as
the organizational units for the mitotic spindle
apparatus. Therefore, an aberrant number of
centrosomes may be aneuploidogenic by pre-
venting proper chromosomal segregation. The
induction of aneuploidy was posited as the
most likely mechanism of arsenic carcinogene-
sis (NRC 1999, 2001). ID1 also protects
against apoptosis through activation of the
nuclear factor kappa B signaling pathway (Ling
et al. 2003). Higher ID1 levels in p53(+) cells
may therefore promote survival. ID1 basal lev-
els are elevated in a variety of cancers, and ID1
is induced during malignant transformation of
rat liver cells by arsenic (Chen et al. 2001).
Consequently, ID1 induction by arsenite may
play an important role in the mechanism of
arsenic carcinogenesis by allowing for survival
of cells progressing through aberrant mitosis
and inducing abnormal chromosome numbers.  
Loss of p53 function as seen in many
tumors has been suggested to allow cells to
bypass cell cycle checkpoints after DNA dam-
age and to enter a nonmitotic state (Erenpreisa
and Cragg 2001). Our results suggest p53
plays an important role in prevention of arsen-
ite-induced mitotic arrest and also in apoptosis
consequent to the arrest. The prevention of
mitotic arrest–associated apoptosis is likely a
key event in arsenic-induced carcinogenesis
because it predisposes cells to aneuploidy.
Understanding the link between p53 and pre-
vention of apoptosis associated with arsenite-
induced mitotic arrest will provide essential
information regarding the mechanism of
arsenic carcinogenesis and also help identify a
key target for cancer chemotherapeutics.
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